Murat Söker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Murat Söker has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Veysiye Hülya Üzel
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Türkiye
5 shared publications - Deniz Yilmaz Karapinar
Department of Pediatrics Ege University Faculty of Medicine Izmir Turkey
2 shared publications - Emine Zengin
Kocaeli University Faculty of Medicine, Division of Pediatric Hematology, Department of Pediatrics, Kocaeli, Türkiye
2 shared publications - Hale Ören
Dokuz Eylül University Faculty of Medicine, Division of Pediatric Hematology, Department of Pediatrics, İzmir, Türkiye
2 shared publications - Kahraman Öncel
Of and , of
2 shared publications - Namık Yaşar Özbek
Department of Pediatric Hematology Ankara Bilkent City Hospital Ankara Turkey
2 shared publications
Latest Publications
- Open Access
Clinical Characteristics and Treatment Patterns in Children with Sickle Cell Anemia in Southeastern Türkiye: A Retrospective Single-Center Study
Background/Objectives: We aimed to describe clinical burden, treatment patterns, and reported adherence in children with presumed HbSS in Southeastern Türkiye. Methods: This retrospective single-center study included 41 children with sufficient clinical records covering 2011–2021; the retrospective chart review was conducted in 2025, and clinical events after 2021 were not included. Diagnosis was supported by hemoglobin electrophoresis at presentation to our center and parental electrophoresis results. Complete molecular records were unavailable. Annual pain-crisis frequency was the average of hospital-documented events over follow-up. Results: There were 24 girls and 17 boys; mean age at last assessment was 9.49 ± 4.55 years. Fifteen children (36.6%) averaged ≥3 pain crises/year. Hydroxyurea had been prescribed to 38 children: 34 reported regular use and four adolescents reported irregular use at the last assessment. Three two-year-old children had not started treatment. The ≥3-crises/year category included 8/34 regular users, 4/4 irregular users, and 3/3 untreated children. An exploratory comparison among prescribed patients yielded a two-sided Fisher exact p-value of 0.0067. No hematologic toxicity requiring dose reduction or treatment discontinuation was documented. Eight children received chronic transfusions and deferasirox. Acute chest syndrome and ischemic stroke were documented in three and two children, respectively. Conclusions: This series distinguishes treatment prescription, reported regular use, and age-related non-initiation within a population with ongoing morbidity. The different timeframes for adherence and crisis assessment and the small subgroups preclude causal interpretation of treatment effects.
Open AccessClinical Characteristics and Treatment Patterns in Children with Sickle Cell Anemia in Southeastern Türkiye: A Retrospective Single-Center Study
Background/Objectives: We aimed to describe clinical burden, treatment patterns, and reported adherence in children with presumed HbSS in Southeastern Türkiye. Methods: This retrospective single-center study included 41 children with sufficient clinical records covering 2011–2021; the retrospective chart review was conducted in 2025, and clinical events after 2021 were not included. Diagnosis was supported by hemoglobin electrophoresis at presentation to our center and parental electrophoresis results. Complete molecular records were unavailable. Annual pain-crisis frequency was the average of hospital-documented events over follow-up. Results: There were 24 girls and 17 boys; mean age at last assessment was 9.49 ± 4.55 years. Fifteen children (36.6%) averaged ≥3 pain crises/year. Hydroxyurea had been prescribed to 38 children: 34 reported regular use and four adolescents reported irregular use at the last assessment. Three two-year-old children had not started treatment. The ≥3-crises/year category included 8/34 regular users, 4/4 irregular users, and 3/3 untreated children. An exploratory comparison among prescribed patients yielded a two-sided Fisher exact p-value of 0.0067. No hematologic toxicity requiring dose reduction or treatment discontinuation was documented. Eight children received chronic transfusions and deferasirox. Acute chest syndrome and ischemic stroke were documented in three and two children, respectively. Conclusions: This series distinguishes treatment prescription, reported regular use, and age-related non-initiation within a population with ongoing morbidity. The different timeframes for adherence and crisis assessment and the small subgroups preclude causal interpretation of treatment effects.
- Open Access
- 15 September 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (10) , 422
Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association
- 15 September 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (10) , 422
Open AccessOutcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association
- Open Access
- 26 December 2025
- Published by Zeus Publishing in Journal of Medical and Dental Investigations
- Vol. 6
Retrospective analysis of demographic and clinical characteristics and treatment outcomes of pediatric acute lymphoblastic leukemia patients
Aim: This study aimed to compare treatment outcomes (mortality and relapse) between two pediatric acute lymphoblastic leukemia (ALL) protocols (TR-ALL BFM 2000 vs ALL-IC-BFM 2009) and to describe the demographic, clinical, and laboratory characteristics of patients treated at a single center (2010–2015). Methods: We retrospectively reviewed the medical records of 121 children (<18 years) diagnosed with ALL and treated with either TR-ALL BFM 2000 or ALL-IC-BFM 2009. Baseline characteristics, risk group, immunophenotype, protocol, relapse status, and survival status were recorded. Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate (p < 0.05). Results: The cohort was 53.7% male, with a mean age at diagnosis of 7.55 ± 3.89 years. B-cell ALL accounted for 78.5% and T-cell ALL for 21.5%. The overall mortality rate was 11.6% (14/121), and relapse occurred in 5.8% (7/121) of patients. Mortality differed by risk group (SRG 6.5%, IRG 7.3%, HRG 23.5%; p = 0.036). Relapse was higher in T-cell ALL than in B-cell ALL (23.1% vs 1.1%; p = 0.001). Compared with ALL-IC-BFM 2009, TR-ALL BFM 2000 was associated with higher mortality (19.2% vs 5.8%; p = 0.022) and relapse (11.5% vs 1.4%; p = 0.019). Conclusion: In this single-center retrospective cohort study, the high-risk group was associated with higher mortality, and the T-cell immunophenotype was associated with higher relapse. Patients treated with ALL-IC-BFM 2009 had lower crude mortality and relapse rates than those treated with TR-ALL BFM 2000; however, these protocol comparisons should be interpreted cautiously, given potential confounding and limited event numbers.
- 26 December 2025
- Published by Zeus Publishing in Journal of Medical and Dental Investigations
- Vol. 6
Open AccessRetrospective analysis of demographic and clinical characteristics and treatment outcomes of pediatric acute lymphoblastic leukemia patients
Aim: This study aimed to compare treatment outcomes (mortality and relapse) between two pediatric acute lymphoblastic leukemia (ALL) protocols (TR-ALL BFM 2000 vs ALL-IC-BFM 2009) and to describe the demographic, clinical, and laboratory characteristics of patients treated at a single center (2010–2015). Methods: We retrospectively reviewed the medical records of 121 children (<18 years) diagnosed with ALL and treated with either TR-ALL BFM 2000 or ALL-IC-BFM 2009. Baseline characteristics, risk group, immunophenotype, protocol, relapse status, and survival status were recorded. Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate (p < 0.05). Results: The cohort was 53.7% male, with a mean age at diagnosis of 7.55 ± 3.89 years. B-cell ALL accounted for 78.5% and T-cell ALL for 21.5%. The overall mortality rate was 11.6% (14/121), and relapse occurred in 5.8% (7/121) of patients. Mortality differed by risk group (SRG 6.5%, IRG 7.3%, HRG 23.5%; p = 0.036). Relapse was higher in T-cell ALL than in B-cell ALL (23.1% vs 1.1%; p = 0.001). Compared with ALL-IC-BFM 2009, TR-ALL BFM 2000 was associated with higher mortality (19.2% vs 5.8%; p = 0.022) and relapse (11.5% vs 1.4%; p = 0.019). Conclusion: In this single-center retrospective cohort study, the high-risk group was associated with higher mortality, and the T-cell immunophenotype was associated with higher relapse. Patients treated with ALL-IC-BFM 2009 had lower crude mortality and relapse rates than those treated with TR-ALL BFM 2000; however, these protocol comparisons should be interpreted cautiously, given potential confounding and limited event numbers.
- 25 October 2021
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 63 (5) , 875-883
Evaluation of retinal nerve fiber layer and choroidal thickness with spectral domain optical coherence tomography in children with sickle cell anemia
Background. The aim of this study is to examine the thickness of choroidal, macular and peripapillary retinal nerve fiber layer by spectral-domain optical coherence tomography (SD-OCT) in pediatric patients with sickle cell anemia (SCA) without retinopathy. Methods. A total of 75 children (30 SCA patients (Group 1) and 45 healthy individuals (Group 2) were included in the study. Macular (central, superior, inferior, nasal, temporal), choroidal (subfoveal, at nasal distances from the central fovea of 1000 μm [N1], 2000 μm [N2], 3000 μm [N3], at temporal distances from the central fovea of 1000 μm [T1], 2000 μm [T2], 3000 μm [T3]) and RNFL (average, temporal, superotemporal, inferotemporal, nasal, inferonasal and superonasal) measurements were performed by SD-OCT. These parameters were compared with healthy children with similar demographic characteristics. Results. The mean age was 14.11±3.86 (11-18) in sickle cell anemia patients and 13.15± 2.69 (10-18) in the healthy control group. Of the patients, 56.6% (n=17) of Group 1 and 44.4% (n=20) of Group 2 were male. Choroidal measurements made in the subfoveal, N1, N2, N3, T1, T2 and T3 quadrants showed that the choroid was thinner in 6 quadrants in SCA patients compared to the healthy group (p = 0.003, p = 0.039, p = 0.035, p = 0.595, p = 0.006, p = 0.005, p = 0.047, respectively). In RNFL measurements, there was significant thinning in the temporal, inferotemporal, and nasal quadrants of SCA patients compared to the healthy group. Changes in other quadrants were not significant. Conclusions. SD-OCT is a useful imaging method in the diagnosis and screening in patients with SCA without retinopathy. Early diagnosis of retinopathy during subclinical disease will prevent visual loss in these patients.
- 25 October 2021
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 63 (5) , 875-883
Evaluation of retinal nerve fiber layer and choroidal thickness with spectral domain optical coherence tomography in children with sickle cell anemia
Background. The aim of this study is to examine the thickness of choroidal, macular and peripapillary retinal nerve fiber layer by spectral-domain optical coherence tomography (SD-OCT) in pediatric patients with sickle cell anemia (SCA) without retinopathy. Methods. A total of 75 children (30 SCA patients (Group 1) and 45 healthy individuals (Group 2) were included in the study. Macular (central, superior, inferior, nasal, temporal), choroidal (subfoveal, at nasal distances from the central fovea of 1000 μm [N1], 2000 μm [N2], 3000 μm [N3], at temporal distances from the central fovea of 1000 μm [T1], 2000 μm [T2], 3000 μm [T3]) and RNFL (average, temporal, superotemporal, inferotemporal, nasal, inferonasal and superonasal) measurements were performed by SD-OCT. These parameters were compared with healthy children with similar demographic characteristics. Results. The mean age was 14.11±3.86 (11-18) in sickle cell anemia patients and 13.15± 2.69 (10-18) in the healthy control group. Of the patients, 56.6% (n=17) of Group 1 and 44.4% (n=20) of Group 2 were male. Choroidal measurements made in the subfoveal, N1, N2, N3, T1, T2 and T3 quadrants showed that the choroid was thinner in 6 quadrants in SCA patients compared to the healthy group (p = 0.003, p = 0.039, p = 0.035, p = 0.595, p = 0.006, p = 0.005, p = 0.047, respectively). In RNFL measurements, there was significant thinning in the temporal, inferotemporal, and nasal quadrants of SCA patients compared to the healthy group. Changes in other quadrants were not significant. Conclusions. SD-OCT is a useful imaging method in the diagnosis and screening in patients with SCA without retinopathy. Early diagnosis of retinopathy during subclinical disease will prevent visual loss in these patients.
- Open Access
- 25 August 2021
- Published by Galenos Yayinevi in Güncel Pediatri
- Vol. 19 (2) , 162-167
Evaluation of 36 Patients with Rare Factor Deficiency
- 25 August 2021
- Published by Galenos Yayinevi in Güncel Pediatri
- Vol. 19 (2) , 162-167
Open AccessEvaluation of 36 Patients with Rare Factor Deficiency
- Open Access
- 29 September 2020
- Published by Hacettepe University - Medical School in Acta Medica
- Vol. 51 (3) , 38-43
Comparison of Compliance of Different Iron Chelators Including Original and Bioequivalents of Deferasirox
Objective: The current iron chelation therapy regimens include deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX) in transfusion-dependent patients. Compliance with iron-chelating therapy is one of the significant determinants of mortality and morbidities related to iron loading in chronically transfused patients. This survey aims to compare the compliance and the satisfaction of DFO, DFP, and DFX formulations in patients who have iron-overloading in three hematology centers from Turkey. Moreover, bioequivalent (generic) formulations of dispersible DFX tablet compared with the original formulation in terms of taste and treatment compliance. Patients and Methods: A written questionnaire with a list of pre-set questions was applied to measure patient-reported outcomes to a total of 85 patients, where 77 had beta-thalassemia major, 7 had beta-thalassemia intermedia, and 1 had sickle cell anemia diagnoses. Results: The patients’ median age at enrollment was 15 years (range 7 – 42). The compliance was below 50% in 8 (18.6%), 4 (16%), and 5 (6.7%) in patients receiving DFO, DFP, and DFX, respectively. Additionally the compliance was below 80% in 16 (37.2%), 9 (36%), and 17 (22.6%) in patients receiving DFO, DFP, and DFX, respectively. It was found that 39 (47%) patients had compliance problems due to the dispersible DFX tablet formulations’ taste, except combination therapies. There was no difference between the currently used oral chelators in terms of taste and treatment compliance. Conclusion: This study draws attention to compliance problems in patients with iron-loading anemias, partly due to the unpleasant taste of DFX. Improving patient satisfaction and compliance with iron-chelator therapy may reduce complications of iron overload.
- 29 September 2020
- Published by Hacettepe University - Medical School in Acta Medica
- Vol. 51 (3) , 38-43
Open AccessComparison of Compliance of Different Iron Chelators Including Original and Bioequivalents of Deferasirox
Objective: The current iron chelation therapy regimens include deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX) in transfusion-dependent patients. Compliance with iron-chelating therapy is one of the significant determinants of mortality and morbidities related to iron loading in chronically transfused patients. This survey aims to compare the compliance and the satisfaction of DFO, DFP, and DFX formulations in patients who have iron-overloading in three hematology centers from Turkey. Moreover, bioequivalent (generic) formulations of dispersible DFX tablet compared with the original formulation in terms of taste and treatment compliance. Patients and Methods: A written questionnaire with a list of pre-set questions was applied to measure patient-reported outcomes to a total of 85 patients, where 77 had beta-thalassemia major, 7 had beta-thalassemia intermedia, and 1 had sickle cell anemia diagnoses. Results: The patients’ median age at enrollment was 15 years (range 7 – 42). The compliance was below 50% in 8 (18.6%), 4 (16%), and 5 (6.7%) in patients receiving DFO, DFP, and DFX, respectively. Additionally the compliance was below 80% in 16 (37.2%), 9 (36%), and 17 (22.6%) in patients receiving DFO, DFP, and DFX, respectively. It was found that 39 (47%) patients had compliance problems due to the dispersible DFX tablet formulations’ taste, except combination therapies. There was no difference between the currently used oral chelators in terms of taste and treatment compliance. Conclusion: This study draws attention to compliance problems in patients with iron-loading anemias, partly due to the unpleasant taste of DFX. Improving patient satisfaction and compliance with iron-chelator therapy may reduce complications of iron overload.
- Open Access
- 17 March 2020
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 37 (3) , 139-144
OUTCOMES OF ELTROMBOPAG TREATMENT AND DEVELOPMENT OF IRON DEFICIENCY IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA IN TURKEY
Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 +/- 4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of >= 50x109/L was 11.6 +/- 8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8 +/- 9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.
- 17 March 2020
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 37 (3) , 139-144
Open AccessOUTCOMES OF ELTROMBOPAG TREATMENT AND DEVELOPMENT OF IRON DEFICIENCY IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA IN TURKEY
Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 +/- 4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of >= 50x109/L was 11.6 +/- 8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8 +/- 9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.
- Open Access
- 11 June 2019
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 36 (4) , 274-277
Fertility in Patients with Thalassemia and Outcome of Pregnancies: a Turkish Experience
Objective: In recent years, the rates of marriage and pregnancy are increasing in patients with thalassemia major. The aim of the present study was to investigate the fertility rate of thalassemic patients and the course of pregnancies in terms of mother and infant health. Materials and Methods: In this observational study patients with major hemoglobinopathy were evaluated regarding marital status, the need for assisted reproductive techniques, fertility rate, iron status, and pregnancy complications. Results: Seventeen female patients gave birth to 21 healthy infants. About one-third of the patients needed assisted reproductive techniques. Thalassemia major patients showed increased serum ferritin levels from 1203 +/- 1206 mu g/L. at baseline to 1880 +/- 1174 mu g/L at the end of pregnancy. All babies are still alive and healthy. Conclusion: Pregnancy in patients with thalassemia can be safe for the mother and newborn with close monitoring and a multidisciplinary approach.
- 11 June 2019
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 36 (4) , 274-277
Open AccessFertility in Patients with Thalassemia and Outcome of Pregnancies: a Turkish Experience
Objective: In recent years, the rates of marriage and pregnancy are increasing in patients with thalassemia major. The aim of the present study was to investigate the fertility rate of thalassemic patients and the course of pregnancies in terms of mother and infant health. Materials and Methods: In this observational study patients with major hemoglobinopathy were evaluated regarding marital status, the need for assisted reproductive techniques, fertility rate, iron status, and pregnancy complications. Results: Seventeen female patients gave birth to 21 healthy infants. About one-third of the patients needed assisted reproductive techniques. Thalassemia major patients showed increased serum ferritin levels from 1203 +/- 1206 mu g/L. at baseline to 1880 +/- 1174 mu g/L at the end of pregnancy. All babies are still alive and healthy. Conclusion: Pregnancy in patients with thalassemia can be safe for the mother and newborn with close monitoring and a multidisciplinary approach.
- 1 July 2016
- Published by Elsevier in Journal Of Neuroradiology
- Vol. 43 (4) , 297-302
MRI-based evaluation of the factors leading to pituitary iron overload in patients with thalassemia major
- 1 July 2016
- Published by Elsevier in Journal Of Neuroradiology
- Vol. 43 (4) , 297-302
MRI-based evaluation of the factors leading to pituitary iron overload in patients with thalassemia major
- Open Access
- 5 September 2014
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 31 (3) , 313-314
A Rare Cause of Recurrent Oral Lesions: Chediak- Higashi Syndrome
- 5 September 2014
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 31 (3) , 313-314
Open AccessA Rare Cause of Recurrent Oral Lesions: Chediak- Higashi Syndrome